ABBV AbbVie Inc

8-K Current Report

Filed: March 4, 2026

Health Care

Pharmaceutical Preparations

AbbVie Inc (ABBV) 8-K current report filed with SEC EDGAR on March 4, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• Total debt issuance $8.0B across 7 tranches, maturities ranging 2028–2066, completed March 4, 2026
• Floating rate tranche $750M due 2028; fixed rates range from 3.775% (2028) to 5.650% (2066)

+3 more insights

Other AbbVie Inc 8-K Filings

8-K Feb 26, 2026

Get deeper insights on AbbVie Inc

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.